NE3107 (Bezisterim) for Early Parkinson's Disease (NCT06757010)
Trial Overview
flowchart TD
NE3107__Bezisterim__Early_Park["NE3107 Bezisterim Early Parkinsons Trial"]
NE3107__Bezisterim__Early_Park["Parkinson"]
NE3107__Bezisterim__Early_Park -->|"related to"| NE3107__Bezisterim__Early_Park
style NE3107__Bezisterim__Early_Park fill:#81c784,stroke:#333,color:#000
NE3107__Bezisterim__Early_Park["Trial"]
NE3107__Bezisterim__Early_Park -->|"related to"| NE3107__Bezisterim__Early_Park
style NE3107__Bezisterim__Early_Park fill:#81c784,stroke:#333,color:#000
NE3107__Bezisterim__Early_Park["Field"]
NE3107__Bezisterim__Early_Park -->|"related to"| NE3107__Bezisterim__Early_Park
style NE3107__Bezisterim__Early_Park fill:#81c784,stroke:#333,color:#000
style NE3107__Bezisterim__Early_Park fill:#4fc3f7,stroke:#333,color:#000
| Field | Value |
|-------|-------|
| NCT Number | NCT06757010 |
| Status | RECRUITING |
| Phase | Phase 2 |
| Sponsor | BioVie Inc. |
| Intervention | NE3107 (Bezisterim) |
| Mechanism | TNF-alpha inhibitor, anti-inflammatory |
| Route | Oral |
| Study Design | Randomized, double-blind, placebo-controlled |
| Indication | Early Parkinson's disease |
| Enrollment | 60 subjects (estimated) |
| Treatment Duration | 12 weeks |
| Dosage | 20 mg NE3107 BID (40 mg daily) vs. placebo |
Introduction and Clinical Significance
...NE3107 (Bezisterim) for Early Parkinson's Disease (NCT06757010)
Trial Overview
Mermaid diagram (expand to render)
| Field | Value |
|-------|-------|
| NCT Number | NCT06757010 |
| Status | RECRUITING |
| Phase | Phase 2 |
| Sponsor | BioVie Inc. |
| Intervention | NE3107 (Bezisterim) |
| Mechanism | TNF-alpha inhibitor, anti-inflammatory |
| Route | Oral |
| Study Design | Randomized, double-blind, placebo-controlled |
| Indication | Early Parkinson's disease |
| Enrollment | 60 subjects (estimated) |
| Treatment Duration | 12 weeks |
| Dosage | 20 mg NE3107 BID (40 mg daily) vs. placebo |
Introduction and Clinical Significance
Parkinson's disease (PD) is the second most common neurodegenerative disorder, affecting approximately 10 million people worldwide. The disease is characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta, leading to the hallmark motor symptoms including bradykinesia, resting tremor, rigidity, and postural instability. Additionally, non-motor symptoms such as cognitive impairment, depression, sleep disorders, and autonomic dysfunction significantly impact quality of life[@caldi2021].
Despite decades of research, current treatments remain primarily symptomatic, focusing on dopamine replacement therapy with levodopa and dopamine agonists. While these interventions provide substantial benefit, they do not halt or slow disease progression. The development of disease-modifying therapies remains an urgent unmet need[@tansey2018].
Neuroinflammation has emerged as a critical driver of PD pathogenesis. Tumor necrosis factor-alpha (TNF-α) is a pro-inflammatory cytokine that plays a central role in the neuroinflammatory processes contributing to dopaminergic neuron degeneration. Elevated TNF-α levels have been documented in the brains, cerebrospinal fluid, and peripheral blood of PD patients, correlating with disease severity and progression[@bauer2020][@chen2023].
Drug Profile: NE3107 (Bezisterim)
Mechanism of Action
NE3107 (Bezisterim) is a novel oral TNF-alpha inhibitor developed by BioVie Inc. Unlike monoclonal antibody TNF inhibitors (such as infliximab, adalimumab, etanercept) that target TNF-α systemically, NE3107 is designed as a small molecule that can penetrate the blood-brain barrier and target neuroinflammation directly in the central nervous system[@mcguire2019].
The molecular mechanism involves:
TNF-α signaling blockade: NE3107 inhibits TNF-α binding to its receptors (TNFR1 and TNFR2), preventing downstream inflammatory signaling
NF-κB pathway inhibition: By blocking TNF receptor activation, NE3107 prevents NF-κB nuclear translocation and transcription of pro-inflammatory genes
Microglial modulation: Reduces activation of microglia, the resident immune cells of the brain that become chronically activated in PD
Blood-brain barrier penetration: Designed to cross the BBB to act directly on CNS immune cells and neuronsPharmacological Properties
NE3107 has demonstrated favorable pharmacological properties in preclinical studies:
- Oral bioavailability: Designed for convenient daily oral administration
- BBB penetration: Small molecule structure allows access to CNS targets
- Selective TNF inhibition: Targets TNF-α specifically without broad immunosuppression
- Anti-inflammatory efficacy: Demonstrated reduction in pro-inflammatory cytokine production
Comparison with Other TNF Inhibitors
The therapeutic landscape for TNF inhibition in neurodegeneration includes several approaches[@bokhari2023]:
| Drug | Type | BBB Penetration | Use in PD |
|------|------|-----------------|-----------|
| NE3107 | Small molecule | Yes | Under investigation |
| Infliximab | Monoclonal antibody | Limited | Experimental |
| Etanercept | Recombinant protein | Limited | Experimental |
| Adalimumab | Monoclonal antibody | Limited | Experimental |
The key advantage of NE3107 is its small molecule design, which enables direct targeting of neuroinflammation in the brain rather than merely peripheral TNF-α.
Preclinical Evidence in Parkinson's Disease
Neuroinflammatory Mechanisms in PD
TNF-α contributes to Parkinson's disease pathogenesis through multiple mechanisms[@kaur2022]:
Direct neurotoxicity: TNF-α can induce apoptosis in dopaminergic neurons
Microglial activation: Creates a self-perpetuating cycle of neuroinflammation
Blood-brain barrier disruption: Increases permeability allowing peripheral immune cell infiltration
α-synuclein aggregation: TNF-α promotes misfolding and aggregation of α-synuclein
Mitochondrial dysfunction: Impairs complex I activity in dopaminergic neuronsEvidence from Preclinical Models
Studies support TNF-α inhibition as a therapeutic strategy for PD[@chen2023]:
- Dopaminergic neuron protection: TNF-α blockade preserves tyrosine hydroxylase-positive neurons in the substantia nigra
- Motor function improvement: Animal models show improved performance in rotarod and cylinder tests
- Inflammation reduction: Decreased microglial activation and reduced pro-inflammatory cytokine expression
- α-synuclein mitigation: Reduced α-synuclein phosphorylation and aggregation
Mechanism Validation
The neuroprotective effects of TNF-α inhibition are mediated through[@bauer2020]:
Microglial modulation: Reduction in activated microglia in the substantia nigra
Cytokine attenuation: Decreased TNF-α, IL-1β, and IL-6 in brain tissue
Oxidative stress reduction: Mitigation of oxidative damage markers
Mitochondrial protection: Preservation of mitochondrial function in dopaminergic neurons
Anti-apoptotic effects: Prevention of caspase-3 activation and neuronal apoptosisStudy Design
- Design: Randomized, double-blind, placebo-controlled, parallel-group
- Population: Early Parkinson's Disease (idiopathic PD within 18 months of diagnosis)
- Treatment-naïve: No prior levodopa or dopamine agonists
Eligibility Criteria
Inclusion
- Age 45-80 years
- Idiopathic Parkinson's Disease diagnosed within 18 months
- Treatment-naïve (no prior levodopa, carbidopa, or similar dopaminergic drugs)
Exclusion
- Secondary parkinsonism
- Prior dopaminergic therapy
- Significant cognitive impairment
Endpoints
Primary Endpoint
- Change from baseline in MDS-UPDRS Part III at 12 weeks
Secondary Endpoints
- Change from baseline in MDS-UPDRS Parts I and II at 12 weeks
- Percent of subjects with improvement in Clinical Global Impression
Trial Sites
Quest Research Institute — Farmington Hills, MI
Dent Neurologic — Amherst, NY
Science 37 (Nationwide Site) — Morrisville, NC
NeuroScience Research Center, LLC — Canton, OHScientific Rationale
TNF-α in Parkinson's Disease Pathogenesis
TNF-α plays a central role in PD pathogenesis through multiple pathways[@tansey2018]:
Neuroinflammation cycle: Chronic microglial activation creates self-sustaining inflammation
Neuronal apoptosis: TNF-α signaling through TNFR1 triggers apoptotic pathways
Synaptic dysfunction: TNF-α impairs neurotransmitter release and synaptic plasticity
Blood-brain barrier breakdown: Increases CNS infiltration of peripheral immune cellsClinical Evidence in PD Patients
Studies have demonstrated elevated TNF-α in PD patients:
- Elevated CSF TNF-α: Increased levels in cerebrospinal fluid correlating with disease severity
- Serum biomarkers: Elevated peripheral TNF-α associated with motor progression
- PET imaging: Increased TSPO binding indicating microglial activation
- Post-mortem studies: Elevated TNF-α in substantia nigra of PD brains
Why Oral Small Molecule?
The choice of an oral small molecule TNF inhibitor addresses key limitations of existing biologic therapies:
- BBB penetration: Small molecules can reach CNS targets
- Oral administration: Convenience over intravenous biologics
- Peripheral immunosuppression avoidance: Local CNS effect without systemic immunosuppression
- Infection risk: Lower infection risk compared to systemic immunosuppression
Rationale for Early Parkinson's Disease
The trial focuses on early-stage Parkinson's disease for several important reasons:
Preserved neurons: Early intervention may protect remaining dopaminergic neurons before extensive loss
Better therapeutic response: Patients with less advanced pathology may respond better to neuroprotective therapy
Disease modification potential: Early intervention offers the greatest opportunity to slow or halt progression
Functional reserve: Greater neuronal reserve allows for more meaningful functional improvementPotential Benefits and Risks
Expected Benefits
Based on preclinical data, NE3107 may provide:
Disease modification: Potential to slow or halt disease progression through neuroprotection
Motor symptom improvement: Possible improvement in tremor, bradykinesia, and rigidity
Non-motor symptom relief: Potential benefits for depression, sleep, and autonomic function
Anti-inflammatory effect: Reduction in chronic neuroinflammation driving neurodegeneration
Complementary mechanism: Works through different pathway than dopaminergic therapiesRisk Considerations
Potential risks include:
- Gastrointestinal effects: Nausea, diarrhea
- Headache: Common in early clinical trials
- Peripheral immunosuppression: Though designed for CNS, systemic effects possible
- Drug interactions: Potential interactions with other medications
- Unknown long-term safety: Limited long-term data in PD population
The targeted mechanism and small molecule design are expected to provide an acceptable risk-benefit profile.
Cross-References and Related Content
For more detailed information, see related pages:
- [TNF Signaling in Neurodegeneration](/mechanisms/tnf-signaling-neurodegeneration) — Detailed mechanism of TNF-α in neurodegeneration
- [Neuroinflammation in Parkinson's](/mechanisms/neuroinflammation-parkinsons) — Background on neuroinflammatory processes
- [Microglial Activation in Parkinson's](/mechanisms/microglia-neuroinflammation) — Role of microglia in PD pathogenesis
- [Parkinson's Disease](/diseases/parkinsons-disease) — Disease overview
- [Anti-inflammatory Therapies for Neurodegeneration](/therapeutics/anti-inflammatory-therapy-neurodegeneration) — Overview of anti-inflammatory approaches
- [TNF Inhibitors in Neurodegeneration](/therapeutics/infliximab-neurodegeneration) — TNF inhibitor therapy overview
- [Dapansutrile for Parkinson's](/clinical-trials/dapansutrile-pd-nct07157735) — Another NLRP3 inflammasome inhibitor in trials
- [BiIB122 (Luma) LRRK2 Inhibitor](/clinical-trials/biib122-luma-lrrk2-inhibitor-pd) — LRRK2 targeting approach
- [AMX0035 (Centaur) for PD](/clinical-trials/amx0035-centaur) — Another neuroprotective approach
Comparison with Other Neuroprotective Approaches
Several disease-modifying approaches are in development for PD:
| Approach | Target | Stage | Mechanism |
|----------|--------|-------|-----------|
| NE3107 | TNF-α | Phase 2 | Anti-inflammatory, neuroprotective |
| Dapansutrile | NLRP3 | Phase 2 | Inflammasome inhibition |
| BiIB122 | LRRK2 | Phase 2 | Kinase inhibition |
| AMX0035 | TDP-43/mitochondrial | Phase 2/3 | Dual mechanism |
| Inosine | Urate | Phase 3 | Antioxidant |
Each approach targets different pathological mechanisms, and multiple successful therapies could potentially be combined for additive benefit.
Conclusion
The Phase 2 clinical trial of NE3107 (Bezisterim) for early Parkinson's disease (NCT06757010) represents an important step toward developing disease-modifying therapies for PD. By targeting TNF-α, a central mechanism of neuroinflammation, NE3107 offers a novel approach that addresses the underlying pathophysiology of PD rather than merely alleviating symptoms.
The scientific foundation supporting this trial includes:
Strong preclinical evidence demonstrating neuroprotection in PD models
Mechanistic rationale linking TNF-α activation to PD pathogenesis
Innovative design as an oral small molecule with BBB penetration
Patient need for disease-modifying therapeutic optionsSuccessful development of NE3107 would not only validate TNF-α inhibition as an effective PD therapy but also establish this approach as a viable strategy for other neurodegenerative disorders characterized by neuroinflammation.
References
[BioVie Inc. "NE3107 (Bezisterim) in Early Parkinson's Disease" (NCT06757010)](https://clinicaltrials.gov/study/NCT06757010)
[BioVie Pipeline - NE3107](https://www.biovie-inc.com/pipeline/ne3107/)
[Chen et al., TNF-α inhibition in Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37254123/)
[Kaur et al., TNF-alpha in Parkinson's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35092841/)
[Bauer et al., Neuroinflammation and TNF-α in PD (2020)](https://pubmed.ncbi.nlm.nih.gov/32194070/)
[Bokhari et al., TNF-alpha inhibitors in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37184982/)
[McGuire et al., Anti-TNF therapy for neurodegenerative disorders (2019)](https://pubmed.ncbi.nlm.nih.gov/31478705/)
[Caldi et al., Peripheral inflammatory markers in PD (2021)](https://pubmed.ncbi.nlm.nih.gov/32977242/)
[Tansey & Goldberg, Neuroinflammation in Parkinson's disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29566955/)
Created: 2026-03-31
Last updated: 2026-03-31